1. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. AntiNMDA-receptor encephalitis: case series and analysis of the effects of antibodies.
Lancet Neurol. (2008) 7:1091–8. doi: 10.1016/S1474-4422(08)70224-2
16. Spatola M, Sabater L, Planagumà J, Martínez-Hernandez E, Armangué T,
Prüss H, et al. Encephalitis with mGluR5 antibodies: symptoms and antibody
effects. Neurology. (2018) 90:e1964–72. doi: 10.1212/WNL.0000000000005614
2. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al.
Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma
inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis,
Morvan’s syndrome and acquired neuromyotonia. Brain. (2010) 133:2734–48.
doi: 10.1093/brain/awq213
17. Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R,
et al. Encephalitis with refractory seizures, status epilepticus, and antibodies
to the GABAA receptor: a case series, characterisation of the antigen,
and analysis of the effects of antibodies. Lancet Neurol. (2014) 13:276–86.
doi: 10.1016/S1474-4422(13)70299-0
3. Levite M. Autoimmune
doi: 10.1038/ni0602-500
18. Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al.
A novel non-rapid-eye movement and rapid-eye-movement parasomnia with
sleep breathing disorder associated with antibodies to IgLON5: a case series,
characterisation of the antigen, and post-mortem study. Lancet Neurol. (2014)
13:575–86. doi: 10.1016/S1474-4422(14)70051-1
epilepsy.
Nat
Immunol.
(2002)
3:500.
4. Ekizoglu E, Tuzun E, Woodhall M, Lang B, Jacobson L, Icoz S, et al.
Investigation of neuronal autoantibodies in two different focal epilepsy syndromes.
Epilepsia. (2014) 55:414-22. doi: 10.1111/epi.12528
19. Titulaer MJ, Höftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, et al.
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor
encephalitis. Ann Neurol. (2014) 75:411–28. doi: 10.1002/ana.24117
5. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al.
ILAE classification of the epilepsies: position paper of the ILAE commission for
classification and terminology. Epilepsia. (2017) 58:512–21. doi: 10.1111/epi.13709
20. Baysal-Kirac L, Tuzun E, Erdag E, Ulusoy C, Vanli-Yavuz EN, Ekizoglu
E, et al. Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic
findings. J Neurol. (2016) 263:455–66. doi: 10.1007/s00415-015-8002-2
6. Quek AM, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al.
Autoimmune epilepsy: clinical characteristics and response to immunotherapy.
Arch Neurol. (2012) 69:582–93. doi: 10.1001/archneurol.2011.2985
21. Steriade C, Mirsattari SM, Murray BJ, Wennberg R. Subclinical temporal
EEG seizure pattern in LGI1-antibody–mediated encephalitis. Epilepsia. (2016)
57:e155–60. doi: 10.1111/epi.13436
7. Toledano M, Britton JW, McKeon A, Shin C, Lennon VA, Quek
AM, et al. Utility of an immunotherapy trial in evaluating patients
with presumed autoimmune epilepsy. Neurology. (2014) 82:1578–86.
doi: 10.1212/WNL.0000000000000383
22. Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al.
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann
Neurol. (2011) 69:892–900. doi: 10.1002/ana.22307
8. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A
clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. (2016)
15:391–404. doi: 10.1016/S1474-4422(15)00401-9
23. Akobeng AK. Understanding diagnostic
operating
characteristic
curves.
Acta
Paediatr.
doi: 10.1111/j.1651-2227.2006.00178.x
9. Dubey D, Alqallaf A, Hays R, Freeman M, Chen K, Ding K et al. Neurological
autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol. (2017)
74:397–402. doi: 10.1001/jamaneurol.2016.5429
24. Kanazawa K, Matsumoto R, Shimotake A, Kinoshita M, Otsuka A, Watanabe
O, et al. Persistent frequent subclinical seizures and memory impairment after
clinical remission in smoldering limbic encephalitis. Epileptic Disord. (2014)
16:312–7. doi: 10.1684/epd.2014.0664
10. de Bruijn MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, Thijs
RD, Majoie MJM, et al. Antibodies contributing to focal epilepsy signs and
symptoms score. Ann Neurol. (2021) 89:698–710. doi: 10.1002/ana.26013
25. Jang Y, Kim DW, Yang KI, Byun JI, Seo JG, et al. Clinical
approach to autoimmune epilepsy. J Clin Neurol. (2020) 16:519–29.
doi: 10.3988/jcn.2020.16.4.519
11. Sakamoto M, Matsumoto R, Togawa J, Hashi Y, Takeyama H, Kobayashi
K, et al. Proposal of a diagnostic algorithm for autoimmune epilepsy:
preliminary investigation of its utility. Rinsho Shinkeigaku. (2018) 58:609–16.
doi: 10.5692/clinicalneurol.cn-001180
26. Steriade C, Moosa ANV, Hantus S, Prayson RA, Alexopoulos A, Rae-Grant
A. Electroclinical features of seizures associated with autoimmune encephalitis.
Seizure. (2018) 60:198–204. doi: 10.1016/j.seizure.2018.06.021
12. Dalmau J. NMDA receptor encephalitis and other antibody-mediated
disorders of the synapse: the 2016 cotzias lecture. Neurology. (2016) 87:2471–82.
doi: 10.1212/WNL.0000000000003414
27. McGinty RN, Handel A, Moloney T, Ramesh A, Fower A, Torzillo E, et al.
Clinical features which predict neuronal surface autoantibodies in new-onset focal
epilepsy: implications for immunotherapies. J Neurol Neurosurg Psychiatry. (2021)
92:291–4. doi: 10.1136/jnnp-2020-325011
13. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A,
Houghton DJ, et al. Treatment-responsive limbic encephalitis identified by
neuropil antibodies: MRI and PET correlates. Brain. (2005) 128:1764–77.
doi: 10.1093/brain/awh526
28. Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin
Neurol. (2016) 12:1–13. doi: 10.3988/jcn.2016.12.1.1
14. Wandinger KP, Leypoldt F, Junker R. Autoantibody-mediated
encephalitis. Dtsch Arztebl Int. (2018) 115:666–73. doi: 10.3238/arztebl.
2018.0666
29. von Rhein B, Wagner J, Widman G, Malter MP, Elger CE, Helmstaedter
C. Suspected antibody negative autoimmune limbic encephalitis: outcome of
immunotherapy. Acta Neurol Scand. (2017) 135:134–41. doi: 10.1111/ane.12575
15. Marignier R, Chenevier F, Rogemond V, Sillevis Smitt P, Renoux C,
Cavillon G, et al. Metabotropic glutamate receptor type 1 autoantibody–associated
cerebellitis: a primary autoimmune disease? Arch Neurol. (2010) 67:627–30.
doi: 10.1001/archneurol.2010.51
Frontiers in Neurology
tests 3: receiver
(2007) 96:644–7.
30. Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA,
et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy.
Epilepsia. (2017) 58:1181–9. doi: 10.1111/epi.13797
09
frontiersin.org
Sakamoto et al.
10.3389/fneur.2022.902157
37. Geis C, Planagumà J, Carreño M, Graus F, Dalmau J. Autoimmune seizures
and epilepsy. J Clin Invest. (2019) 129:926–40. doi: 10.1172/JCI125178
31. Mitsueda-Ono T, Ikeda A, Inouchi M, Takaya S, Matsumoto R, Hanakawa
T, et al. Amygdalar enlargement in patients with temporal lobe epilepsy. J Neurol
Neurosurg Psychiatry. (2011) 82:652–7. doi: 10.1136/jnnp.2010.206342
38. Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C. Imaging of
autoimmune encephalitis – relevance for clinical practice and hippocampal
function. Neuroscience. (2015) 309:68–83. doi: 10.1016/j.neuroscience.
2015.05.037
32. Malter MP, Widman G, Galldiks N, Stoecker W, Helmstaedter C, Elger CE,
et al. Suspected new-onset autoimmune temporal lobe epilepsy with amygdala
enlargement. Epilepsia. (2016) 57:1485–94. doi: 10.1111/epi.13471
39. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, et al.
Anti-NMDA receptor encephalitis in Japan: long-term outcome without
tumor removal. Neurology. (2008) 70:504–11. doi: 10.1212/01.wnl.0000278388.90
370.c3
33. Bower SP, Vogrin SJ, Morris K, Cox I, Murphy M, Kilpatrick CJ, et al.
Amygdala volumetry in “imaging-negative” temporal lobe epilepsy. J Neurol
Neurosurg Psychiatry. (2003) 74:1245–9. doi: 10.1136/jnnp.74.9.1245
34. Takaya S, Ikeda A, Mitsueda-Ono T, Matsumoto R, Inouchi M,
Namiki C, et al. Temporal lobe epilepsy with amygdala enlargement:
a morphologic and functional study. J Neuroimaging. (2014) 24:54–62.
doi: 10.1111/j.1552-6569.2011.00694.x
40. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J.
Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian
teratoma. Ann Neurol. (2005) 58:594–604. doi: 10.1002/ana.20614
41. Hegen H, Reindl M. Recent developments in MOG-IgG associated
neurological disorders. Ther Adv Neurol Disord. (2020) 13:1756286420945135.
doi: 10.1177/1756286420945135
35. Minami N, Morino M, Uda T, Komori T, Nakata Y, Arai N, et al.
Surgery for amygdala enlargement with mesial temporal lobe epilepsy: pathological
findings and seizure outcome. J Neurol Neurosurg Psychiatry. (2015) 86:887–94.
doi: 10.1136/jnnp-2014-308383
42. Piquet AL, Khan M, Warner JEA, Wicklund MP, Bennett JL, Leehey
MA, et al. Novel clinical features of glycine receptor antibody syndrome:
a series of 17 cases. Neurol Neuroimmunol Neuroinflamm. (2019) 6:e592.
doi: 10.1212/NXI.0000000000000592
36. Guerin J, Watson RE, Carr CM, Liebo GB, Kotsenas AL. Autoimmune
epilepsy: findings on MRI and FDG-PET. Br J Radiol. (2019) 92:20170869.
doi: 10.1259/bjr.20170869
Frontiers in Neurology
10
frontiersin.org
...
論文の公開元へ
